Download PDF
Hamostaseologie 1981; 01(04): 160-164
DOI: 10.1055/s-0038-1656604
Originalarbeiten
Schattauer GmbH

Prophylaxe venöser Thromboembolien bei hämatologischen Erkrankungen

H. Rasche
1   Abteilung Innere Medizin III/Sektion Hämostaseologie des Zentrums für Innere Medizin der Universität Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Im Gegensatz zur operativen Medizin und bestimmten Teilgebieten der inneren Medizin (z.B. Kardiologie) fehlen in der Hämatologie systematische Untersuchungen zur Häufigkeit und Prophylaxe intravital auftretender thromboembolischer Komplikationen unter Verwendung objektiver Metho-den (z.B. Radiojod-Fibrinogentest). Bis zum Vorliegen entsprechender Befunde ist es zweckmäßig, die gesicherten Erfahrungen anderer Disziplinen im Sinne eines Analogieschlusses für das Spezialgebiet Hämatologie verfügbar zu machen. Diese Überlegung gilt insbesondere beim Vorhegen allgemeiner Risikofaktoren wie fortgeschrittenes Lebensalter, körperliche Immobilisation, thrombotische Komplikationen in der Anamnese, Übergewicht und maligne Grundkrankheit (z.B. malignes Lymphom). In diesen Fällen sind die bekannten Maßnahmen der physikalischen und medikamentösen Thromboembolieprophyla-xe großzügig einzusetzen. Bei myeloproliferativen Syndromen, reaktiven Thrombozytosen, bestimmten Formen der hämolytischen Anämie sowie seltenen Koagulopathien müssen besondere Gesichtspunkte berücksichtigt werden.

 

  • LITERATUR

  • 1 Adams T, Schutz L, Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand. J. Haematol 1974; 13: 215
    PubMedGoogle Scholar
  • 2 Amris C. J, Hansen N. E. Coagulation and fibrinolytic studies in paroxysmal nocturnal haemoglobinemia. Acta med. Scand 1968; 184: 551
    PubMedGoogle Scholar
  • 3 Beck E. A. Abnormal fibrinogen (fibrinogen »Baltimore«) as a cause of a familial he-morrhagig disorder. Blood 1964; 24: 853
    PubMedGoogle Scholar
  • 4 Beck E. A. Congenital abnormalities of fibrinogen. Clin. Haematol 1979; 8: 169
    PubMedGoogle Scholar
  • 5 Bensinger T. A, Logue G. L, Randle-son R. W. Hemorrhagic thrombocythemia: control of postsplenectomy thrombocytosis with melphalan. Blood 1970; 36: 61
    PubMedGoogle Scholar
  • 6 Berger S, Aledort L. M, Gilbert H. S, Hanson J. P, Wasserman L. R. Abnormalities of platelet function in patients with polycytha-emia vera. Cancer Res 1973; 33: 2683
    PubMedGoogle Scholar
  • 7 Bjanke B, Herrn P, Blomback M. Neonatal aortic thrombosis a possible clinical manifestation of congenital antithrombin III deficiency. Actapaediat. scand 1974; 63: 297
    PubMedGoogle Scholar
  • 8 Boughton B. J, Corbett W. E. N, Ginsburg A. D. Myeloproliferative disorders: a paradox of in vivo and in vitro platelet function. J. Clin. Pathol 1977; 30: 228
    CrossrefPubMedGoogle Scholar
  • 9 Cardamone J. M, Edson J. R, McArthur J. R, Jakob H. S. Abnormalities of platelet function in myeloproliferative disorders. J. Amer. Med. Ass 1972; 221: 270
    CrossrefPubMedGoogle Scholar
  • 10 Cohen J, Djoldetti M, Karb M, de Vries A. Thrombocytosis with impaired platelet adhesiveness and platelet factor 3 availability. New Ist. Contrib. Clin. Sci 1966; 9: 20
    PubMedGoogle Scholar
  • 11 Dacie J. V, Lewis S. M. Paroxysmal nocturnal haemoglobinuria: clinical manifestations haematology, and nature of the disease. Ser. Haematol 1972; 5: 3
    PubMedGoogle Scholar
  • 12 Didisheim P, Bunting D. Abnormal platelet function in myelofibrosis. Amer. J. Clin. Path 1966; 45: 566
    PubMedGoogle Scholar
  • 13 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thrombos. Diathes. haemorrh 1965; 13: 516
    PubMedGoogle Scholar
  • 14 Flute P. T. Disorders of fibrinogen synthesis. Brit. Med. Bull 1977; 33: 253
    CrossrefPubMedGoogle Scholar
  • 15 Fritzsche W, Martin H. Properdin andHämo-lyse. Zur Hemmung der Hämolyse von Ery-throcyten von Kranken mit paroxysmaler nächtlicher Hämoglobinurie durch Heparin. Klin. Wschr 1957; 35: 1166
    CrossrefPubMedGoogle Scholar
  • 16 Fuchs G, Egbring R, Havemann K. A new case of dydfibrinogenaemia. Fibrinogen Marburg. 5. Congr. Intern. Soc. Thrombos. Haemostas; Abstr: 1975: 222
    Google Scholar
  • 17 Ginsburg A. D. Thrombocytosis and thrombocythemia. In Root W. S, Berlin N. J. (eds) Physiological Pharmacology. Academic Press N.Y: 1974: 199
    Google Scholar
  • 18 Ginsburg A. D. Platelet function in patients with high platelet counts. Ann. Intern. Med 1975; 82: 506
    CrossrefPubMedGoogle Scholar
  • 19 Hansen M. S, Christensen B. E, Jonsson V. The effect of acetyl salicylic acid and dipyridamole on thromboembolic complications in splenectomized patients with myelofibrosis. Scand. J. Haematol 1979; 23: 111
    PubMedGoogle Scholar
  • 20 Hardistry R. M, Wolff H. H. Hemorrhagic thrombocythemia: A clinical and laboratory study. Brit. J. Haematol 1955; 1: 390
    CrossrefPubMedGoogle Scholar
  • 21 Hartmann R. C, Kolhouse J. F. Viewpoints on the management of paroxysmal nocturnal hemoglobulinuria. Ser. Haematol 1972; 3: 42
    PubMedGoogle Scholar
  • 22 Hirsch J, McBride J. A, Dacie J. V. Throm-bo-embolism and increased platelet adhesiveness in postsplenectomy thrombocytosis. Aust. Ann. Med 1960; 15: 122
    PubMedGoogle Scholar
  • 23 Hirsh J, Dacie J. V. Persistent postsplen-ectomie thrombocytosis and thromboembolism: a consequence of continuing anaemia. Brit. J. Haematol 1966; 12: 44
    CrossrefPubMedGoogle Scholar
  • 24 Imperato C. Di, Dettori A. G. Ipofibrinoge-nemia congenita con fibrinoastenia. Helvet. paed. Acta 1958; 13: 380
    PubMedGoogle Scholar
  • 25 Inceman S, Tangren Y. Platelet defects in myeloproliferative disorders. Ann. N. Y. Acad. Sci 1972; 201: 251
    CrossrefPubMedGoogle Scholar
  • 26 Kernoff P. B. A, McNicol G. P. Normal and abnormal fibrinolysis. Brit. Med. Bull 1977; 33: 239
    CrossrefPubMedGoogle Scholar
  • 27 Lane J. L, Biggs R. The natural inhibitors of coagulation. In Poller L. (ed.) Recent advances on blood coagulation. Churchill-Livingstone; London: 1977: 123
    Google Scholar
  • 28 Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis myelosclerosis, extramedul-lary hematopoiesis, undifferentiated MPD and hemorrhagic thrombocythemia. Sem. Hematol 1975; 12: 409
    PubMedGoogle Scholar
  • 29 Linker H, Maier T, Reuter H, Junginger T. Plättchenzahl und Plättchenfunktion nach Splenektomie. Dtsch. Ärzteblatt 1981; 14: 677
    PubMedGoogle Scholar
  • 30 Martinez J, Shapiro S. S, Holburn R. R. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states. Blood 1973; 42: 35
    PubMedGoogle Scholar
  • 31 Marx R. Antithrombin III: Praktische Bedeutung und neues therapeutisches Prinzip. Therapiewoche 1981; 31: 4295
    PubMedGoogle Scholar
  • 32 McClure P. D, Ingram G. J. C, Stacey R. S, Glass U. H, Matchrett M. O. Platelet function test in thrombocythemia and thrombocytosis. Brit. J. Haematol 1966; 12: 478
    CrossrefPubMedGoogle Scholar
  • 33 Mondhiry H. A. B, Bilezekion S. B, Nossel H. L. Fibrinogen New York: an abnormal fibrinogen associated with thromboembolism. Blood 1975; 45: 607
    PubMedGoogle Scholar
  • 34 Moser K. M, Shea J. G. The relationship between pulmonary infarctioncor pulmonale and the sickle cell states. Amer. J. Med 1957; 22: 561
    CrossrefPubMedGoogle Scholar
  • 35 Neemeh J. A, Bowie E. J. W, Thompson J. H, Didisheim P, Owen C. A. Quantitation of platelet aggregation in myeloproliferative disorders. Amer. J. Clin. Pathol 1972; 57: 336
    PubMedGoogle Scholar
  • 36 Payne P. R, Holt J. M, Nearne P. B. Paroxysmal nocturnal haemoglobinuria: parturition complicated by presumed hepatic vein thrombosis. J. Obstr. Gynecol 1968; 75: 1066
    PubMedGoogle Scholar
  • 37 Peytreman R, Rhodes R. S, Hartman R. C. Thrombosis in paroxysmal nocturnal hemoglobinuria with particular reference to progressive diffuse hepatic venous thrombosis. Ser. Haematol 1972; 3: 115
    PubMedGoogle Scholar
  • 38 Rasche H. Hämostasestörungen bei Poly-cythaemia vera und ihre Beeinflussung durch die Radiophosphor-Behandlung. In Marx R, Thies H. A. (Hrsg.) Strahlen, Blutgerinnung und Hämostase. Thie-me; Stuttgart: 1974: S205
    Google Scholar
  • 39 Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Europ. J. Cancer 1977; 13: 1053
    CrossrefPubMedGoogle Scholar
  • 40 Schramm W, Marx R. Die Behandlung thrombophiler Diathesen durch Substitution mit Antithrombin-III-Konzentrat. In Deutsch E, Lechner K. (Hrsg.) Fibrino-lyse, Thrombose, Hämostase. Schat-tauer; Stuttgart: 1980: S491
    Google Scholar
  • 41 Samama M, Soria J, Soria C, Bousser J. Congenital and familial dysfibrinogenaemia without bleeding tendency, Xll. Intern. Soc. Haematol. Abstr; Congr: 1968: 179
    Google Scholar
  • 42 Samama M, Soria J, Soria C. Congenital and acquired dysfibrinogenaemia. In Poller L. (ed.) Recent advances in blood coagulation. Churchill-Livingstone; London: 1977: 313
    Google Scholar
  • 43 Sas G, Blasko G, Bankeguyi D, Jakob J, Palos L. A. Abnormal antithrombin III (antithrombin III (»Budapest«) as a cause of a familial thrombophilia. Thrombos. Diathes. haemorrh 1974; 32: 105
    PubMedGoogle Scholar
  • 44 Semeraro N, Vermylen J. Evidence that washed human platelets possess factor X activator activity. Brit. J. Haematol 1977; 36: 107
    CrossrefPubMedGoogle Scholar
  • 45 Semeraro N, Furmurola D, Mertens F, Vermylen J. Evidence that endotoxins enhance the factor X activator activity of washed human platelets. Brit. J. Haematol 1978; 38: 243
    CrossrefPubMedGoogle Scholar
  • 46 Semeraro N, Cortellazzo S, Colucci M, Barbui T. A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythemia. Thrombos. Res 1979; 16: 795
    CrossrefPubMedGoogle Scholar
  • 47 Sirchia G, Lewis S. M. Paroxysmal nocturnal haemoglobinuria. Clin. Haematol 1975; 4: 199
    PubMedGoogle Scholar
  • 48 Soria J, Soria C. Dysfibrinogenemie familiale avec anomalie d’aggregation des monomeres. Fibrinogene Paris III. Pathol. Biol 1974; 22: 72
    PubMedGoogle Scholar
  • 49 Spaet T. H, Lejnieks J, Gaynov E, Goldstein M. L. Defective platelets in essential thrombocythemia. Arch. Intern. Med 1969; 124: 135
    CrossrefPubMedGoogle Scholar
  • 50 Strubing P. Paroxysmale Haemoglobinurie. Dtsch. Med. Wschr 1882; 8: 1
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Taylor D. D, Senhauser D. A, Cavazos F. Thrombocytopathy associated with nonleucemic megakaryocytic myelosis. Amer. J. Clin. Path 1968; 49: 662
    PubMedGoogle Scholar
  • 52 Walsh P. N, Murphy S, Barry W. E. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thrombos. Haemostas 1977; 38: 1085
    PubMedGoogle Scholar
  • 53 Weinfeld A, Branchög J, Kutti J. Platelets in the myeloproliferative syndrome. Clin. Haematol 1975; 4: 373
    PubMedGoogle Scholar
  • 54 Winckelmann G, Augustin R, Bandilla K. Congenital dysfibrinogenaemia. Report of a new family (fibrinogen »Wiesbaden«). 2nd Congr. Int. Soc. Thrombos; Haemostas. Abstr: 1971: 41
    Google Scholar
  • 55 Younger J, Umlas J. Rapid reduction of platelet count in essential haemorrhagic thrombocythemia by discontinuous flow pla-teletpheresis. Am. J. Med 1978; 64: 659
    CrossrefPubMedGoogle Scholar
  • 56 Zimmermann D, Bell W. R. Venous thrombosis and splenic rupture in paroxysmal nocturnal hemoglobinuria. Amer. J. Med 1980; 68: 275
    CrossrefPubMedGoogle Scholar
  • 57 Zucker S, Mielke C. H. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications. J. Lab. Clin. Med 1972; 80: 385 70/164
    PubMedGoogle Scholar